Lenalidomide (CC-5013)

For research use only.

Catalog No.S1029

84 publications

Lenalidomide (CC-5013) Chemical Structure

CAS No. 191732-72-6

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 70 In stock
USD 147 In stock
USD 407 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Lenalidomide (CC-5013) has been cited by 84 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Targets
TNF-α [1]
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC NXfG[no3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xWWJKSzVyPUKuNVUxOzhizszN M3uxXXNCVkeHUh?=
L-363 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;6bXNKSzVyPUKuPVIzOTJizszN MoDKV2FPT0WU
JAR NYXhWZZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\HcI1KSzVyPUKuPVcxODFizszN MULTRW5ITVJ?
EoL-1-cell M16xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzHeWZJUUN3ME20MlExPTF3IN88US=> MVnTRW5ITVJ?
BT-549 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZwMkG4OFkh|ryP MXjTRW5ITVJ?
SK-NEP-1 M4OyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTdwOEm1NVIh|ryP NGHV[FZUSU6JRWK=
BV-173 NVXpOo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2xTWM2OD16Lk[3OVg2KM7:TR?= MVTTRW5ITVJ?
HMV-II MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFyLkCxO|Ih|ryP MXrTRW5ITVJ?
HCC1806 NVjObZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFzLkS0Olch|ryP NVrB[G5KW0GQR1XS
KASUMI-1 NXTUbFh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLkW3NUDPxE1? MWPTRW5ITVJ?
SK-MEL-28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfyTWM2OD1zMT65O|Y1KM7:TR?= NHHwZYZUSU6JRWK=
RPMI-8226 NG\pR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF{Lk[yOFEh|ryP NELMZ2RUSU6JRWK=
T47D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV25UmxDUUN3ME2xN{4zODl7IN88US=> NUjTNYxxW0GQR1XS
HOP-62 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzYTWM2OD1zMz60PEDPxE1? MYPTRW5ITVJ?
A2058 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zPRmlEPTB;MUOuPFE6QSEQvF2= NIrt[HpUSU6JRWK=
SW620 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrZXRKSzVyPUG0MlI1PzNizszN NGTNV|NUSU6JRWK=
LCLC-103H NVezTZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDb2JXUUN3ME2xOE41QDl{IN88US=> MVrTRW5ITVJ?
HAL-01 NGTWO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTQSVVKSzVyPUG0MlU4QTZizszN MV7TRW5ITVJ?
PANC-08-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHEcYxKSzVyPUG0MlkyODhizszN MYnTRW5ITVJ?
COLO-684 M17NcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;jU3lKSzVyPUG1MlM6PzlizszN NHXxS3JUSU6JRWK=
DEL M4PX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTITWM2OD1zNT60PVkh|ryP MnfYV2FPT0WU
K5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF4LkG0PFYh|ryP NF3jXYRUSU6JRWK=
SK-MEL-24 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrFOpI3UUN3ME2xOk41PjV{IN88US=> M{PwXHNCVkeHUh?=
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF4LkWyPVch|ryP NF;xNYdUSU6JRWK=
H9 M{K0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vSW2lEPTB;MU[uOlI3KM7:TR?= MVzTRW5ITVJ?
EM-2 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF5LkG0N{DPxE1? NUHx[G96W0GQR1XS
HSC-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17WcmlEPTB;MUeuOlYxOSEQvF2= MnLIV2FPT0WU
IGROV-1 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5Lke4N{DPxE1? M3O1bnNCVkeHUh?=
TE-1 M3fS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF5Lkm5Olgh|ryP MlP2V2FPT0WU
LN-405 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHBNlhKSzVyPUG5MlkxPzZizszN M3zTTXNCVkeHUh?=
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjscplvUUN3ME2yNE4{PTd|IN88US=> MXnTRW5ITVJ?
MOLT-4 NEXSZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJyLkW3OVkh|ryP M3rWSHNCVkeHUh?=
RS4-11 NHi0T2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITPOHVKSzVyPUKyMlE2PjNizszN M2fMVHNCVkeHUh?=
ES3 NYHST5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjRTWM2OD1{Mj62PVY{KM7:TR?= M1jvNHNCVkeHUh?=
SBC-1 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ|Lki2PVYh|ryP MXLTRW5ITVJ?
CTV-1 NX\CVm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTlXpc5UUN3ME2yOU4xOTR7IN88US=> M3XpSnNCVkeHUh?=
HuP-T3 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG5TWM2OD1{NT60NFA6KM7:TR?= NIPsWY1USU6JRWK=
HCC2218 M4PVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vVV2lEPTB;MkWuOVQxPyEQvF2= M3PH[XNCVkeHUh?=
HDLM-2 NX3u[|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHz[|VKSzVyPUK4MlIxOjZizszN MlLWV2FPT0WU
ABC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEixV3lKSzVyPUK5MlY6PzRizszN MonNV2FPT0WU
MV-4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC5TWM2OD1{OT63N|E4KM7:TR?= NFLxTY1USU6JRWK=
WM-115 NEjOdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfRfGc2UUN3ME2zNE4{ODl7IN88US=> Mnf0V2FPT0WU
SW1990 NX76e45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfTSGtKSzVyPUOwMlM{KM7:TR?= MX7TRW5ITVJ?
HCC70 NXvmfXZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNyLkezOFYh|ryP MXrTRW5ITVJ?
KYSE-520 NID0e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LiTmlEPTB;M{CuPFg{QSEQvF2= NYfvZlRCW0GQR1XS
JEG-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNzLkG2NVQh|ryP MnX0V2FPT0WU
C8166 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjZTWM2OD1|MT6yNlc1KM7:TR?= MVHTRW5ITVJ?
SK-OV-3 M1Tlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNzLk[3OVUh|ryP MWTTRW5ITVJ?
NCI-H526 NXX4dZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDGTWM2OD1|Mj62PFMh|ryP M4XNT3NCVkeHUh?=
NKM-1 M{\hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSxTWM2OD1|Mj65OVY5KM7:TR?= M1zmWXNCVkeHUh?=
ECC10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e3RmlEPTB;M{SuO|Q1OyEQvF2= MXXTRW5ITVJ?
A2780 MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfRTWM2OD1|NT6zOlAyKM7:TR?= M37WbXNCVkeHUh?=
KY821 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC0dHhKSzVyPUO1Mlc3QDFizszN NF3yXXhUSU6JRWK=
MKN1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHWbFZRUUN3ME2zOk4zOTN5IN88US=> NI\tb4RUSU6JRWK=
EKVX MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXkN5NEUUN3ME2zO{41OjF{IN88US=> MYDTRW5ITVJ?
EW-16 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7FbmJzUUN3ME2zPE4{QDh3IN88US=> NXXU[olnW0GQR1XS
CTB-1 NVnYbJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz4TmNsUUN3ME2zPU44Pzh7IN88US=> M{nMU3NCVkeHUh?=
COR-L105 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfYeYdKSzVyPUSwMlQ4PDZizszN MoLxV2FPT0WU
NCI-SNU-5 M{\Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRzLkKwOlkh|ryP M4DVUnNCVkeHUh?=
Mewo MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nsVWlEPTB;NEGuPVg4OSEQvF2= NXuxUo5bW0GQR1XS
BCPAP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXzTWM2OD12Mz63PVE4KM7:TR?= MkfuV2FPT0WU
KARPAS-45 M3zDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S5bGlEPTB;NESuNlc4PiEQvF2= NVG2NFVmW0GQR1XS
NCI-H1693 NYDMeo9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD12Nj62PVg3KM7:TR?= Mlu4V2FPT0WU
H-EMC-SS NHWwc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR6LkOyNlQh|ryP MkPaV2FPT0WU
697 NUK2Zo81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVyLkO1OFUh|ryP NIfRNW5USU6JRWK=
KP-N-YS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q2UWlEPTB;NUKuN|E1OiEQvF2= MX3TRW5ITVJ?
NCI-H1304 NYm3fnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfLeYtKSzVyPUWyMlcxOjRizszN NXnTd|VRW0GQR1XS
NOS-1 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX65UmxDUUN3ME21Nk45PTV7IN88US=> MYfTRW5ITVJ?
NCI-H2342 NWPEdXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\YSlNKSzVyPUWzMlA2ODhizszN MXfTRW5ITVJ?
KYSE-270 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\rcmlEPTB;NUOuOlM3PCEQvF2= NVXxN3VzW0GQR1XS
LU-135 NWDlZ5lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j2d2lEPTB;NUWuNVg2OyEQvF2= MWrTRW5ITVJ?
OE33 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nmPGlEPTB;NUWuPFE5KM7:TR?= NX6wenpwW0GQR1XS
ML-2 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yTWM2OD13NT65OFg6KM7:TR?= M3OxU3NCVkeHUh?=
KMOE-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTV4LkK4PVMh|ryP M2TKRXNCVkeHUh?=
Daoy NV\DUVluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXJR2lKSzVyPUW2MlMzODRizszN NIHQ[5NUSU6JRWK=
KNS-62 NE\Ve|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XaUGlEPTB;NUeuNFE1OiEQvF2= NHTtToFUSU6JRWK=
NBsusSR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPzVWRWUUN3ME21O{42PzB3IN88US=> NXXGO5g6W0GQR1XS
UACC-257 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvBUHlTUUN3ME21PE43OjZ2IN88US=> M{XlW3NCVkeHUh?=
LU-139 NYHuUnB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HmO2lEPTB;NUiuPFI3KM7:TR?= MlTWV2FPT0WU
CAL-85-1 M3;3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTV6Lki2OFMh|ryP NWS0RW5FW0GQR1XS
NCI-H720 NVTsXm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTV6Lki5OFIh|ryP NV\vV|NKW0GQR1XS
MLMA M1rCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTV7LkC5NUDPxE1? NUDM[ld4W0GQR1XS
A3-KAW M4HYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTV7LkK4NFkh|ryP M4XVTHNCVkeHUh?=
Ramos-2G6-4C10 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOzSZV[UUN3ME21PU43Ojh5IN88US=> M1PmS3NCVkeHUh?=
A388 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXhcnFKSzVyPU[wMlQ1QSEQvF2= Mo\6V2FPT0WU
LAMA-84 NFXMXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHXUXZKSzVyPU[wMlk6ODVizszN NGXIVINUSU6JRWK=
GCT M1rWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5d3ZKSzVyPU[xMlA4QDZizszN MV\TRW5ITVJ?
K-562 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTYb2tPUUN3ME22NU42OzN|IN88US=> NUHITYIxW0GQR1XS
NCI-H1666 NYrLeJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnNWlEPTB;NkGuPFc2KM7:TR?= MkfOV2FPT0WU
NCI-H1993 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzXS2ZKSzVyPU[zMlQxPDNizszN NHviNIJUSU6JRWK=
NCI-H358 M3H2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf4Z|lKSzVyPU[1MlAyOjFizszN NUn6cW1EW0GQR1XS
NB6 M1zHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTWbW9KSzVyPU[1Mlk5QCEQvF2= MmjMV2FPT0WU
HCE-T NXXYNZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZ5LkC3PVgh|ryP M3fScnNCVkeHUh?=
DOK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZ5LkS5OFgh|ryP NXi3XnFJW0GQR1XS
HT-1376 M1SzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHlTWM2OD14OT64N|E1KM7:TR?= MlPxV2FPT0WU
NEC8 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnpSo5MUUN3ME23NE4yOjR|IN88US=> M{joO3NCVkeHUh?=
G-402 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fKU2lEPTB;N{CuPVM6PSEQvF2= M3TzPXNCVkeHUh?=
GR-ST NELvUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdzLkG3NkDPxE1? NGPxeVNUSU6JRWK=
QIMR-WIL M1u2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jRfmlEPTB;N{GuOFQ{PCEQvF2= MYjTRW5ITVJ?
CHP-212 M1Tsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmcY1YUUN3ME23NU46PjVizszN MnraV2FPT0WU
KU812 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rPbmlEPTB;N{KuPVcxOiEQvF2= NG\3OmtUSU6JRWK=
Becker NInGOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTd|LkG0PFkh|ryP MYPTRW5ITVJ?
ChaGo-K-1 NGXNSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTd2Lke0PFYh|ryP MX\TRW5ITVJ?
A498 NH7VZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r3U2lEPTB;N{SuPVMxQCEQvF2= MojpV2FPT0WU
NCI-H69 NVPuW5ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTd3Lke2OlMh|ryP NXiwOFJQW0GQR1XS
NCI-H209 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTd6Lk[xOFch|ryP MVnTRW5ITVJ?
CAL-33 MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;hOmlEPTB;N{iuPVk{QSEQvF2= MUnTRW5ITVJ?
COLO-680N M3S5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTd7LkGwNFch|ryP MnvuV2FPT0WU
D-283MED NEn4cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvYTo1KSzVyPUe5MlgyOiEQvF2= NXnpSnlyW0GQR1XS
ATN-1 NV;FWnJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2wTWM2OD16MT6xNVg4KM7:TR?= NUTEOFhrW0GQR1XS
NCI-N87 NECzSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HYR2lEPTB;OEGuO|I6PiEQvF2= NVXrNmhnW0GQR1XS
MHH-NB-11 M3GycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[2dWlEPTB;OEGuPFg1QSEQvF2= NXrPNI9sW0GQR1XS
HEL NFHyRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zPfmlEPTB;OEKuOFE{PCEQvF2= M3T2Z3NCVkeHUh?=
NB69 NH7ObYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD16Mz6wNFM{KM7:TR?= NGfFcGxUSU6JRWK=
MPP-89 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD3TWM2OD16Mz6yOVc2KM7:TR?= NWry[o1oW0GQR1XS
COLO-829 NEGzfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTh3LkS5NVIh|ryP MknoV2FPT0WU
ONS-76 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Szd2lEPTB;OEWuO|kxQCEQvF2= M4nqd3NCVkeHUh?=
EW-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXwR3c2UUN3ME24Ok4zODN{IN88US=> MXLTRW5ITVJ?
EW-11 NVXqd2dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fLTGlEPTB;OE[uOFM{PiEQvF2= MkT3V2FPT0WU
SW900 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqTWM2OD16Nz6yNFU{KM7:TR?= NEH1WoJUSU6JRWK=
MOLT-13 NVfYNm5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjMTWM2OD16Nz6yNlQ{KM7:TR?= MkDGV2FPT0WU
HuP-T4 M4jXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTlzLkC0NFUh|ryP M2\JVHNCVkeHUh?=
HCC1419 NUHPR5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37GOWlEPTB;OUGuOlM4PCEQvF2= NWPUXIRLW0GQR1XS
CAL-72 NFn2VlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTl{LkCyNVkh|ryP NXrnTXVzW0GQR1XS
Mo-T NYfzco1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH4TWM2OD17Mj63Olk4KM7:TR?= MmDzV2FPT0WU
OC-314 M2n4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl{Lki4NlEh|ryP MnH2V2FPT0WU
BHT-101 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvoUnBKSzVyPUmzMlEh|ryP MkPGV2FPT0WU
EW-18 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTl|Lki0OlIh|ryP NHuwOm9USU6JRWK=
TE-12 NX3NbmNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTl2LkOwOVUh|ryP NG\6ZYJUSU6JRWK=
MDA-MB-361 NEjHU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTl4LkC1NVYh|ryP MU\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-IKKβ / IKKβ ; 

PubMed: 22698399     


Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10μM) for the indicated times. 

MDM2 / p-MDM2 / p-p53 / p53 ; 

PubMed: 22525275     


(a) Treatment with lenalidomide (Len) increases phosphorylation of ser46 and thr55 of p53. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were prepared and analyzed by Western blotting with antibodies to MDM2, phospho-ser46 of p53, phospho-thr55 of p53 and total p53. (b) Treatment with lenalidomide increases phosphorylation of MDM2 at ser166 and ser186. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were immunoprecipitated using anti-MDM2 antibody. The samples were separated by SDS PAGE and then Western blotted with either anti-MDM2 or antibodies specific to phospho-ser166, phospho-ser186, total phospho-serine or total phospho-threonine of MDM2 as indicated. 

22698399 22525275
Growth inhibition assay
Cell viability; 

PubMed: 22698399     


Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the standard error of the mean (SEM) of triplicates.

22698399
In vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

Protocol

Animal Research:

[5]

- Collapse
  • Animal Models: Adult male Sprague-Dawley rats bearing HUVECs cells
  • Dosages: 50 mg/kg and 250 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.26
Formula

C13H13N3O3

CAS No. 191732-72-6
Storage powder
in solvent
Synonyms N/A
Smiles C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03660072 Not yet recruiting Other: Non-Interventional Multiple Myeloma Bristol-Myers Squibb January 31 2021 --
NCT04467281 Recruiting Drug: 89Zr-DFO-daratumumab|Diagnostic Test: PET/CT Multiple Myeloma Memorial Sloan Kettering Cancer Center June 30 2020 Phase 2
NCT03779555 Recruiting Other: Medication Event Monitoring System Multiple Myeloma Washington University School of Medicine|Alliance for Clinical Trials in Oncology December 13 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the formulation for mouse injection(i.p.)?

  • Answer:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • Question 2:

    what is the procedure to resuspend this compound?

  • Answer:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Lenalidomide (CC-5013) | Lenalidomide (CC-5013) supplier | purchase Lenalidomide (CC-5013) | Lenalidomide (CC-5013) cost | Lenalidomide (CC-5013) manufacturer | order Lenalidomide (CC-5013) | Lenalidomide (CC-5013) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID